Clinical Trials
3 trialsNCT01200485 2020-01-31
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01564277 2018-01-09
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00628628 2013-08-01
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed